Medscape June 20, 2024
A position statement released by the American Headache Society (AHS) earlier this year recommended adding calcitonin gene-related peptide (CGRP)–targeting medications to the list of first-line therapies for migraine prevention.
The guidance replaces recommendations published in 2021 that advised clinicians consider CGRP therapy only after patients fail at least two classes of oral migraine prevention medications for ≥ 8 weeks.
“Elevating CGRP-targeting therapies to the first line should reduce barriers for patients to receive these effective treatments and bring hope to countless people who experience this invisible, yet debilitating disease,” Andrew Charles, MD, AHS president and the statement’s lead author, said in a press release.
Statement authors said the guidance is designed to reduce patient suffering and dispense with an unnecessary...
Today's Sponsors
Today's Sponsor